Today's Breaking News
- Mylan and Lupin Receive European Marketing Authorization for Nepexto®, Biosimilar Etanercept
- Novo Nordisk reports weight loss of 14.9% (16.9% if taken as intended) in STEP 1 trial
- UCB acquires Engage Therapeutics: Staccato® Alprazolam - A potential solution for acute on-demand seizure management for people living with epilepsy
Latest R&D and Business News
- Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020
- PDS Biotech Announces Clinical Trial of Its Lead Immunotherapy Product, PDS0101, in Combination with Chemoradiotherapy in Advanced Cervical Cancer
- Novavax Awarded Department of Defense Contract for COVID-19 Vaccine
- Intravacc Partners With Wageningen Bioveterinary Research and Utrecht University to Develop an Intranasal COVID-19 Vaccine
- FDA Approves Elixirgen Therapeutics IND Application for Therapy for Telomere Biology Disorders with Bone Marrow Failure
- FDA Approves Antibiotic to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
- Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)
- BAYLX,INC. Announces US FDA Clearance of IND Application for Its Umbilical Cord Tissue Mesenchymal Stem Cells Product to Initiate Clinical Trial in Rheumatoid Arthritis
- Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis
- Alpine Immune Sciences Presents Preclinical Data on Novel Dual BAFF/APRIL Inhibitory Domains for B cell Mediated Autoimmune Diseases at the European Congress of Rheumatology E-Congress 2020
- Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals
- European Commission Grants Marketing Authorisation for DARZALEX (daratumumab) Subcutaneous Formulation for all Currently Approved Daratumumab Intravenous Formulation Indications